Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Alpha-1 Antitrypsin Deficiency
100%
Augmentation Therapy
100%
Personalized Approach
100%
Decline Rate
50%
Emphysema
50%
Risk Factors
33%
Lung Density
33%
Spirometry
16%
Intravenous Administration
16%
Pharmacokinetic Study
16%
Computed Tomography
16%
Specialized Center
16%
Functional Impairment
16%
Working Diagnosis
16%
Lung Disease
16%
Patient Identification
16%
Exacerbation Rate
16%
Approaches to Management
16%
Associated Costs
16%
Low Prevalence
16%
Specific Treatment
16%
Patients at Risk
16%
Slow Progression
16%
Long-term Development
16%
Individualized Approach
16%
Variable Characteristics
16%
Placebo-controlled Clinical Trial
16%
Decline in Lung Function
16%
Interventional Study
16%
Therapeutic Decision-making
16%
Selection of the Best
16%
Consistency Approach
16%
Predictive Biomarker
16%
Lung Damage
16%
Lung Impairment
16%
Cost Identification
16%
Exacerbation History
16%
Medicine and Dentistry
Lung
100%
Alpha 1-Antitrypsin Deficiency
100%
Emphysema
75%
Diseases
75%
Health Care Cost
50%
Decision Making
25%
Biological Marker
25%
Prevalence
25%
Computer Assisted Tomography
25%
Placebo
25%
Observational Study
25%
Functional Disease
25%
Silo-Filler's Disease
25%
Controlled Clinical Trial
25%
Pharmacokinetics
25%
Spirometry
25%
Nursing and Health Professions
Alpha 1 Antitrypsin Deficiency
100%
Emphysema
100%
Diseases
100%
Prevalence
33%
Placebo
33%
Computer Assisted Tomography
33%
Lung Disease
33%
Functional Disease
33%
Spirometry
33%
Biological Marker
33%